Comparing clinicopathological characteristics between these two groups, the mean patient age in the punctate MLH1 group was 73 (range 42-90) years, compared to 58 (range 39-74) years in the intact MLH1 group with isolated PMS2 loss. Of the punctuate MLH1 cases, seven (78%) were female, compared to four (57%) in the intact MLH1 group. All punctuate MLH1 cases and five (71%) of intact MLH1 cases originated in the proximal colon. Neither MLH1 promoter methylation status nor germline MMR gene mutation status were available, but all 16 tumours were microsatellite instability (MSI)-high and four of the nine tumours with punctate MLH1 demonstrated somatic BRAF V600E mutation, compared to none in the intact MLH1 group.
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This article is protected by copyright. All rights reserved. of this phenomenon, although this has not been previously illustrated or described in previous reviews of MMR immunohistochemistry interpretation, to the best of our knowledge. (7)
In summary, awareness of this rare and unusual pattern of MLH1 immunostaining, observed in association with PMS2 loss, is important for accurate pathological reporting and clinical interpretation of MMR immunohistochemistry in CRC, as well as in endometrial cancer. We advise careful scrutiny of MLH1 IHC in any CRC demonstrating loss of PMS2 immunoexpression.
Should a punctate pattern of MLH1 immunostaining be observed, this should be reported as abnormal and further investigation for somatic BRAF mutation and/or MLH1 promoter hypermethylation performed in consideration of the need for germline mutation screening to exclude Lynch syndrome. 
